Zentalis Pharmaceuticals, Inc. (ZNTL)
$2.40-4.76%Close
SELLCRISIS · day 24
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $171M
- Beta
- 1.94
- P/E (TTM)
- -0.98
- Short % float
- 12.27%
- Days to cover
- 4.1
- SI change
- +24.5%
- 1W
- -10.11%
- 1M
- -31.43%
- vs SPY 1W
- -9.97%
- vs SPY 1M
- -33.93%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 12
- VALUE
- 9
- GROWTH
- 45
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-52.8%
REV YoY-
ROE-88.0%
EPS YoY-
ROA-81.2%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.98
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.17
P/FCF-
EV/EBITDA-1.06
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E26.24
ALTMAN Z-
CURR RATIO4.82
ND/EBITDA-
BETA1.94
Company news
FAQ
- What is LOPJLB’s current signal on ZNTL?
- LOPJLB’s latest quantitative signal on Zentalis Pharmaceuticals, Inc. (ZNTL) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ZNTL in?
- Zentalis Pharmaceuticals, Inc. (ZNTL) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Zentalis Pharmaceuticals, Inc. (ZNTL) do?
- Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. T…